Literature DB >> 18221852

In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.

Ronald N Jones1, Thomas R Fritsche, Gary J Moet.   

Abstract

Twenty-three generic intravenous piperacillin/tazobactam products were compared for in vitro activity to the branded formulation (Zosyn, Wyeth, Philadelphia, PA) by disk diffusion and incremental broth microdilution assay methods. All but 1 lot demonstrated significantly decreased activity (-5 to -35%), necessitating further investigations regarding the chemical purity, potency, and therapeutic equivalence of these products worldwide. The average -16% activity across all generic lots was equivalent to underdosing piperacillin/tazobactam by 2.6 g daily for serious clinical infections (4.5 g Q6 h).

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18221852     DOI： 10.1016/j.diagmicrobio.2007.12.010

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  9 in total

1.  Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.

Authors:  Zahra Kassamali; Randall A Prince; Larry H Danziger; John C Rotschafer; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  In vitro Comparison of Generic and Branded Preparations of Amoxicillin with Potassium Clavulanate.

Authors:  Priyanka Pathak; Jayshree Dawane
Journal:  J Clin Diagn Res       Date:  2016-09-01

3.  Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration.

Authors:  Edelberto Silva; Jorge A Díaz; María J Arias; Angela P Hernández; Andrés de la Torre
Journal:  BMC Clin Pharmacol       Date:  2010-01-29

4.  Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.

Authors:  Andres F Zuluaga; Maria Agudelo; John J Cardeño; Carlos A Rodriguez; Omar Vesga
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

5.  Quality and stability of ramipril generics/copies versus reference ramipril (Tritace): a 3-month stability comparative study.

Authors:  Depalmo Galli Angeli; Carlo Trezza
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

6.  Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products of vancomycin.

Authors:  Jorge A Diaz; Edelberto Silva; Maria J Arias; María Garzón
Journal:  BMC Clin Pharmacol       Date:  2011-07-21

7.  Comparison of in vitro activities of meropenem productions on Klebsiella pneumoniae isolated from hospitalized patients.

Authors:  Mohammad Taghi Akhi; Babak Asghari; Mohammed Reza Nahaei; Mohammad Yousef Memar; Abdolaziz Rastegar Lari; Behrooz Naghili; Tahereh Pirzadeh
Journal:  GMS Hyg Infect Control       Date:  2014-08-19

8.  Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model.

Authors:  Andres F Zuluaga; Carlos A Rodriguez; Maria Agudelo; Omar Vesga
Journal:  BMC Res Notes       Date:  2015-10-07

9.  Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.

Authors:  Carlos A Rodriguez; Maria Agudelo; Yudy A Aguilar; Andres F Zuluaga; Omar Vesga
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.